BioCryst Pharmaceuticals reported better-than-expected Q3 2026 results and upheld its 2026 guidance, driven by continued growth of Orladeyo in the hereditary angioedema market. The company’s valuation remains modest, but future growth depends heavily on successful development of its pipeline, especially the drug navenibart. Management is shifting towards external innovation and aims to exceed $1 billion in revenues by 2030 through Orladeyo, navenibart, and BCX17725, while expecting royalty costs to decrease after 2029. A Hold rating is assigned due to near-term competition, pressure on Orladeyo sales, and pivotal navenibart data expected only in Q3 2027.
BioCryst Pharmaceuticals Q3 earnings and pipeline updates provide context for health sector trends. For readers following health stocks, 121 of 150 US health-sector stocks on Pluang rose today. Notable movers include ISRG at USD 485.10 (+10.06%), CNC at USD 74.06 (+9.76%), and ALGN at USD 166.35 (+9.74%), as of Nov 05, 2026 01:21 WIB.
Fox Factory Holding Corp. has appointed Troy Henige as its new Chief Technology Officer (CTO) to lead the company's technology vision, strategy, and product roadmap. This new role aims to enhance innovation, connect engineering strengths across the c...
3M Company has reached a historic $7.35 billion settlement to resolve personal injury claims related to exposure to PFAS, toxic chemicals known as "forever chemicals." The settlement covers about 99% of existing claims, potentially benefiting 115,000...
The global e-learning market is projected to grow from $275.9 billion in 2026 to $506.6 billion by 2032, with a CAGR of 10.62% driven by rising internet connectivity, corporate upskilling demands, and government digital education initiatives. North A...
Sun Life Financial Inc. announced a quarterly dividend increase to $1.00 per common share, up 4 cents from the previous quarter, payable on December 31, 2026, to shareholders of record as of November 25, 2026. Dividends were also declared for various...
Sun Life Financial reported a 9% increase in underlying net income to $1.146 billion for Q3 2026, fueled by strong growth across Canada, Asia, the U.S. stop loss segment, and its GreenOak asset management business. Despite a 29% drop in reported net ...
